Ribozymes (catalytic RNAs,
RNA enzymes) are effective modulators of gene expression because of their simple structure, site-specific cleavage activity, and catalytic potential, and have potentially important implications for cancer gene
therapy. Point mutations in the K-ras oncogene are found in approx 90% of human
pancreatic carcinomas, and can be used as potential targets for specific
ribozyme-mediated reversal of the malignant phenotype. In this study, we focused on in vitro manipulation of
ribozyme targeting of the mutated K-ras oncogene in a human
pancreatic carcinoma cell line. We evaluated the efficacy of an anti-K-ras
hammerhead ribozyme targeted against GUU-mutated
codon 12 of the K-ras gene in cultured
pancreatic carcinoma cell lines. The anti-K-ras
ribozyme significantly reduced cellular K-ras
mRNA level (GUU-mutated
codon 12) when the
ribozyme was transfected into the Capan-1
pancreatic carcinoma cells. The
ribozyme inhibited proliferation of the transfected Capan-1 cells. These results suggested that this
ribozyme is capable of reversing the malignant phenotype in human
pancreatic carcinoma cells.